Overdose on Experimental Weight-Loss Drug Highlights Dangers of Unregulated Online Access

A 32-year-old man developed intractable diarrhea and dehydration after accidentally doubling his weekly dose of retatrutide, an experimental GLP-1/GIP/glucagon agonist bought online. He was hospitalized for four days, recovered, and the case underscores the risks of using non-approved obesity drugs without medical supervision amid a growing black market and strong trial results.